



BEXSON BIOMEDICAL

INVESTOR PRESENTATION

2022

CONFIDENTIAL

This communication contains statements that constitute ‘forward-looking’ statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives, intentions, beliefs, expectations and assumptions or future events, performance or results of performance, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and are not guarantees of future performance and involve risks and uncertainties. Our actual results may differ materially from those described in our forward-looking statements due to various factors, including research and development progress and outcomes, competition, market factors, general economic conditions and other factors described above. We do not intend to update or revise any forward-looking statements, whether because of new information, future events or otherwise.

This communication contains market data related to our business and industry. Such market data includes projections that are based on a number of assumptions. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. The assumptions we have used in making these statements are those we believe are reasonable and most significant to the projections as of the date of this communication. To the extent that our assumptions and other assumed events do not materialize, our actual results may vary substantially from the projected operating and financial information, including our projected financial statements, performance or results, contained in this communication.

We are a biopharmaceutical company focused on existing small molecules for **subcutaneous** delivery solutions

We have developed a proprietary technology platform to disrupt the **\$189B⁽¹⁾** injectable market and enable home health

Lead therapy of **Ketamine** to alleviate reliance on opioids for pain management and address mental health indications

Bexson started on belief **Ketamine** is an essential medicine under-utilized for pain management & mental health indications

Needed to solve for more effective and efficient **delivery** of Ketamine to achieve broader adoption

SubQ would be ideal delivery if could solve for historically associated difficulties

Bexson patented 7-valence salt technology **solved** for SubQ delivery challenges with Ketamine

Realized Bexson tech could be applied to broad classes of ionizable small molecules to **disrupt** \$189B⁽¹⁾ small molecule injectable market

Moving from IV to SubQ would create a new paradigm for **home health** solutions of small molecule therapies

Many molecules delivered IV where kinetic control is required

IV solves for low oral bioavailability, GI side-effects and short half-life

IV treatment is expensive, high procedural burden, uncomfortable & delivered in hospital or clinic only

SubQ is preferred by patients and less expensive than IV

SubQ rarely utilized due to poor tissue tolerance, insufficient concentration, little ability for patterned dosing and lack of delivery solutions

Analog success moving from IV to SubQ


IV to SubQ for **biologics** drove \$132B⁽¹⁾ market for SubQ delivery

Halozyme (NASDAQ: HALO) provides delivery tech. for biologics allowing SubQ delivery - \$6.5B market cap.

Primary Small Molecule Therapeutics

Chemotherapy	Anticoagulants
Antibiotics	Anticonvulsants
Muscle Relaxants	Antivirals
Pain management	

IV to SubQ Biologics Examples



(1) Statista, Projected Global Subcutaneous Biologics market

Little innovation for the delivery of IV small molecules


Bexson utilizes existing small molecules with known safety & efficacy

Proprietary technology combines cyclodextrin acid with free-base API creating 7-valence salt


New formulation tech allows attunement to osmolality and pH while maintaining high potency & solubility - necessary for SubQ

Combining Bexson tech with its exclusive, wearable delivery device provides full solution for SubQ delivery & home health solutions

Acid + free base: 1+1 = 7



MOLECULAR PLATFORM DEVELOPMENT




Technology can be applied to broad variety of small molecules with an ionizable nitrogen

Technology validated across multiple drug classes and therapeutic areas

Feasibility performed on 25+ small molecules to date

Psychedelics & Empathogens




Bexson breathes an 18-year IP life-cycle into established safe psychedelics with a long history of human use and safety

Established primary scaffolds validated with Bexson tech, and basis for highly sought analogs.

Bexson tech provides PK control and short times frames for treatment to match medical economics and psych culture

Essentially the entire Shulgin archive of psychedelics and empathogens is in play



KETAMINE (BB106)

Ketamine is used for a variety of therapies including the treatment of pain and depression in hospitals and outpatient clinics.

Known safety and efficacy


Short half-life requires kinetic control

Potential to reduce opioid use

Established stability with Bexson technology

Large market opportunity and societal need

Add. development programs - mental health indications



FLUMAZENIL (BB206)


Flumazenil injections are indicated for reversal of sedative effects associated with benzodiazepines and overdose.

No existing treatment solution for BZP dependence

Short half-life requires kinetic control

Designed as home health solution to alleviate dependence

Significant health crisis in the U.S.



NALOXONE (BB60X)

Naloxone is an opioid antagonist used to rapidly reverse opioid overdose.

Significant need for longer-acting product

Solves for gaps in current therapeutic solutions

Fits Bexson DNA to aid opioid crisis

Complimentary to ketamine Bexson' therapies

Accelerated regulatory pathways for product and device

INVESTMENT CONSIDERATIONS



Disrupting IV Delivery for Small Molecules

- Lack of innovation
- New pharmacology
- Moves from IV to SubQ
- Enables migration to home health
- \$189B⁽¹⁾ addressable market



Platform of Treatment Opportunities

- Adherence for wide variety of small molecules scaffolds
- Broad applications for platform of small molecule therapies
- De-risked repurposing of existing drugs



Wearable SubQ Delivery Solution

- Exclusivity with Stevanato Group
- Unique, cost effective, wearable system
- Safe delivery
- Solves historical limitations with SubQ
- Full end-user solution



Significant Market Opportunities

- Societal need for reduction of opioid use
- #1 health crisis in US
- Post operative pain market \$36B⁽²⁾ globally
- Opioid segment of market \$22B⁽²⁾ globally
- Out-licensing opportunity



Strong Patent Portfolio

- 1 USPTO granted, 10 additional applications
- 7 valence salt
- Omnibus patent strategy
- Focused on liquid formulation



Experienced Management Team

- Deep regulatory and clinical experience
- Expertise in small molecule pharma
- Industry leadership in ketamine therapy
- Experience through all corporate stages
- ~20 FDA approvals

(1) Coherent Market Insights, Small Molecules Injectable Drugs Market Report

(2) Persistence Market Research



THE BEXSON TEAM

Expertise in pharma and med-tech development
Industry leadership in ketamine therapy
Deep regulatory, clinical and physician experience
Experience through all stages: ideation - clinical - commercialization - IPO



**Gregg
Peterson**

CHIEF EXECUTIVE
OFFICER



**Jeffrey
Becker, MD**

CHIEF SCIENTIFIC OFFICER



**Matthew
Pigeon**

CHIEF FINANCIAL OFFICER



**Rosemary
Gonzales**

VP OF QUALITY



**Sheldon
Moberg**

SR VP DRUG DELIVERY



**Kevin
Bruhn, PHD**

VP CLINICAL
DEVELOPMENT

Over 20 FDA approvals